Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly

Drug Profile

Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly

Alternative Names: 603281-31-8; LY-GSK-3i

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Azepines; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Apoprotein stimulants; Cell cycle modulators; Glycogen synthase kinase 3 inhibitors; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in USA
  • 20 Apr 2010 Pharmacodynamics data from preclinical trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
  • 14 Dec 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top